Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon

CONCLUSIONS: Baseline and on-treatment qHBeAg is a useful biomarker that can identify participants on NA therapy who may benefit from adding or switching to pegylated interferon.PMID:38641023 | DOI:10.1016/j.antiviral.2024.105876

Source: Antiviral Research - April 19, 2024 Category: Virology Authors: Daniel Q Huang Liang Shen Wah Wah Phyo Gavin Cloherty Emily K Butler Mary C Kuhns Anne L McNamara Vera Holzmayer None Jeffrey Gersch Mark Anderson Wei Lyn Yang Jing Hieng Ngu Jason Chang Jessica Tan Taufique Ahmed Yock Young Dan Yin Mei Lee Guan Huei Lee Source Type: research